Bavencio, Inlyta combo meets PFS endpoint in first-line RCC

Merck KGaA (Xetra:MRK) and Pfizer Inc. (NYSE:PFE) said Bavencio avelumab plus Inlyta axitinib met the primary endpoint of improving progression-free survival vs. Sutent sunitinib in the Phase III JAVELIN Renal 101 trial to treat previously untreated advanced renal cell carcinoma.

According to an interim

Read the full 432 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE